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Abstract
One form of programmed cell death (PCD) is apoptosis. Defective apoptosis is 
an indispensable causative factor in the development of cancer that allows cancer 
cells to survive longer and favors the accumulation of oncogenic mutations. Further, 
upregulation of antiapoptotic proteins (e.g., Bcl-2, Mcl-1) and loss of pro-apoptotic 
proteins (e.g., Bid, Bad, Bax, Bak) strongly favors apoptosis evasion. The ability of 
cancer cells to evade apoptosis is critical for the progression and clonal expansion of 
malignantly transformed cells. Defective apoptosis imparts proliferative advantage 
to cancer cells or cells with the potential to become cancerous. The mechanisms 
employed by cancer cells to evade apoptosis can be used in the strategic design of 
therapeutic regimens aimed at exploiting apoptotic signaling networks to ensure 
tumor-specific cell death. Therefore, to ensure tumor-specific cell death, we may 
need to exploit the expression and/or function of different components of apoptotic 
signaling that are critical for maintaining cell survival and are regulated differently 
in tumor cells than normal cells. Both inhibitors of anti-apoptotic proteins and 
activators of pro-apoptotic proteins can be used for cancer therapy. In this chapter, 
we attempted to summarize the knowledge about the molecular mechanisms of 
defective apoptosis that could be translated into the development of novel thera-
peutic agents and therapeutic modalities for cancer treatment.
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1. Introduction
The term apoptosis was coined by Kerr, Wyllie and Currie in 1972 to describe 
a form of programmed cell death. This type of cell death is mediated by intracel-
lular proteolytic enzyme cascades in a highly regulated fashion. The cells that die 
as a result of apoptosis typically do not burst and do not release their intracellular 
contents in the surroundings [1]. As a result apoptosis is typically not associ-
ated with inflammation. In multicellular organisms, this process participates in 
development, tissue homeostasis, and acts as a defense mechanism against the 
formation of genetically altered cells. Apoptosis is a pivotal for maintaining normal 
cell turnover and offers defense strategy against tumorigenesis in multicellular 
organisms. Consequently cells with unrepairable genetic damage or the cells with 
potential to become cancerous are eliminated via apoptosis. Thus aberrant failure 
Regulation and Dysfunction of Apoptosis
2
or deficiency of apoptotic signaling can lead to unregulated growth of geneti-
cally altered cells and subsequently the development of cancer [2]. Similarly, over 
activation of apoptosis may result in excessive death of normal cells and may lead 
to development of neurodegenerative disorders such as autoimmune disorders, 
Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease [3]. Both failure 
of apoptosis and excess of apoptosis are detrimental for an organism. Apoptosis 
is highly programmed biological process that occurs during both physiological 
and pathological states. An in-depth knowledge of apoptosis is critical for under-
standing the pathogenesis of many diseases [4]. For example, cancer is a disease 
condition where little or no apoptosis occurs resulting in unregulated growth of 
genetically altered cells [5]. Therefore, there is need to identify new drugs and new 
chemical entities that can potentially target various aspects of apoptosis in tumor 
cells selectively and specifically. In this chapter, we made an attempt to summa-
rize the knowledge on apoptosis, its molecular mechanism and how defective or 
unregulated apoptosis leads to cancer development and how apoptosis can be used 
for therapeutic intervention of cancer. The process of apoptosis manifest multitude 
of morphological and biochemical changes which can be detected by various cell 
biological techniques.
1.1 Morphological characteristics of apoptosis
During apoptosis, a cell undergoes a series of morphological changes such as 
condensation of cytoplasm, condensation of chromatin, nuclear fragmentation, 
cell rounding, cell shrinkage and blebbing of nuclear and cytoplasmic membranes 
to form membrane-bound fragments. The chromatin condensation typically begins 
at the ends of nuclear envelop that forms a ring-like structure [6]. The chromatin 
condensation continues until it disintegrates into small membrane-bound apoptotic 
bodies. These small bodies are crowded with closely packed cellular organelles and 
smaller fragments of nucleus [6, 7]. These apoptotic bodies are immediately taken 
up by phagocytes such as macrophages, dendritic cells and Langerhans cells. The 
engulfment of these apoptotic bodies by phagocytes occurs without any inflam-
mation and release of intracellular contents. As we know, apoptosis is usually 
considered a non-inflammatory process while necrosis (another mode of cell death) 
activates inflammation. This apoptotic process is typically mediated by the proteo-
lytic cleavage of cellular substrates by caspases, and signaling elements [7, 8]. The 
morphological changes occur in parallel with the activation of a number of complex 
biochemical effector pathways that cause solubilization of the apoptotic cells.
1.2 Biochemical characteristics of apoptosis
Besides morphological changes, an apoptotic cell progresses through a series of 
biochemical changes such as endonucleolytic fragmentation of genomic DNA by 
endogenous DNases which cleave intranucleosomal regions of genomic DNA into 
double stranded DNA (dsDNA) fragments of sizes varying from 180 bp to 200 bp. 
DNA fragmentation is the frequent end point and the widespread marker of apop-
tosis [9]. The DNA fragments that are formed during apoptosis contain single base 
3′ overhangs as well as blunt ends. The DNA fragments formed during apoptosis 
are noticeable as a ladder pattern in the ethidium based-electrophoresis of genomic 
DNA [10]. The most important enzymes that catalyze the cleavage of genomic DNA 
during apoptosis include DNA fragmentation factor (DFF40), caspase activated 
DNase (CAD) and 70-kDa endonuclease (NUC70). In a normal healthy cell, DFF40 
and CAD are retained as inactive heterodimers with inhibitor proteins DFF45 and 
ICAD (inhibitor of CAD). During apoptosis, these DNase are selectively activated 
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upon cleavage by caspase 3. Once activated, DFF40 and CAD are sufficient to 
induce the nuclear morphological changes characteristic of apoptosis. Similarly, 
when isolated HeLa nuclei are incubated with NUC70, the nuclei undergo inter-
nucleosomal DNA fragmentation. NUC70 is a cytoplasmic endonuclease that is 
translocated to the nucleus after the initiation of apoptosis [7, 11].
2. Pathways of apoptosis
There are atleast two fundamental pathways of apoptosis: extrinsic, death 
receptor-mediated pathway and intrinsic, mitochondria-mediated pathway. 
Another important pathway of apoptosis is perforin/granzyme pathway. Apoptosis 
can be initiated through any one of these pathways.
2.1 The extrinsic death receptor pathway
This pathway begins when ligand binds to the death receptor, for example, 
with the attachment of extracellular ligands, like tumor necrosis factor (TNF), Fas 
ligand (Fas-L), TNF-related apoptosis-inducing ligand (TRAIL) to the extracel-
lular domain of transmembrane receptors. There are six death receptors (TNFR1, 
Fas, DR3, DR4 [TRAILR1], DR5 [TRAILR2], and DR6) that have been identi-
fied in mammalian cells (Table 1). While signaling through TNFR1 and DR3 is 
proinflammatory in nature, signaling via other death receptors is predominantly 
pro-apoptotic. The death receptors bind via their intracellular death domain with 
adapter proteins such as Fas-associated death domain (FADD) and TNF receptor-
associated death domain (TRADD). These adaptor proteins, called the Death 
effector Domain (DED) have another protein interaction domain [12]. These 
sequential steps leads to the formation of a death inducing signaling complex 
(DISC), that leads to auto-catalytic activation of procaspase-8 (Figure 1). Active 
caspase-8 activates effector/executioner caspases (cysteine-dependent aspartyl-
specific proteases), which cause cell death by damaging the nucleus and other 
intracellular structures. Once caspase-8 is activated, the execution phase of apop-
tosis is triggered and activated. This type of apoptosis, which is death receptor-
mediated apoptosis, can be inhibited by a protein called c-FLIP. c-FLIP bind to 
FADD and caspase-8, and turns them ineffective. A protein called Toso, has been 
shown to block Fas-induced apoptosis in T cells. This may be due to inhibition of 
caspase-8. The death receptors belong to the tumor necrosis factor (TNF) receptor 
gene superfamily. TNF family contains cysteine-rich extracellular domains and a 
cytoplasmic domain of about 80 amino acids called the “death domain”. This death 
domain plays a critical role in transmitting the death signal from the cell surface to 
the intracellular signaling pathways [13–15].







Death receptors and their cognate ligands.
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2.2 The intrinsic mitochondrial apoptosis pathway
Intrinsic apoptosis is a form of regulated cell death that is activated in response 
to a variety of stimulus such as dearth of growth factors, DNA damage, endoplasmic 
reticulum (ER) stress, and overproduction of reactive oxygen species (ROS). The 
intrinsic pathway is affected by members of the Bcl-2 family proteins such as Bcl-2 and 
Bax. These proteins usually are bound to the outer mitochondrial membrane and act 
as antiapoptotic and pro-apoptotic proteins respectively [6]. In the intrinsic pathway 
the main consequence of proapoptotic signaling is mitochondrial membrane pertur-
bation and release of cytochrome ‘c’ in the cytoplasm. Once released in the cytosol, 
cytochrome ‘c’ forms a complex with apoptotic protease activating factor 1 (APAF1) 
and inactive form of pro-caspase 9, commonly known as apoptosome (Figure 1). This 
complex hydrolyzes adenosine triphosphate (ATP) to cleave and activate caspase 9. 
The initiator caspase 9 then cleaves and activates the executioner caspase 3, caspase 6, 
and caspase 7, resulting in cell apoptosis. The antiapoptotic proteins Bcl-2 and Bcl-XL 
inhibit cytochrome ‘c’ release [8]. The Bcl-2 group of proteins share one to four Bcl2 
homology (BH) domains (i.e., BH1, BH2, BH3, and BH4) [16]. Bax and Bak of the 
Bcl-2 family form pores across the outer mitochondrial membrane. Besides this, Bax 
also continuously cycles between the outer mitochondrial membrane (OMM) and the 
cytosol, and exhibits a quiescent inactive dimeric conformation [17]. Bak constitu-
tively resides at the OMM, where it inserts within hydrophobic C-terminal of voltage 
dependent anion channel 2 (VDAC2). Upon apoptosis induction, mitochondrial pools 
of Bax and Bak undergo direct or indirect activation by pro-apoptotic proteins [16].
The BH3-only proteins are BCL2 binding component 3 or p53, Bcl-2-like 11 
(BIM) [18]. Some internal stimuli cause an increase in mitochondrial membrane 
permeability and these stimulus send the signal to the mitochondria, that form 
mitochondrial outer membrane permeabilization (MOMP). MOMP is most com-
monly mediated via a variety of protein membrane and protein–protein interac-
tions of the B-cell lymphoma 2 protein (Bcl-2) family [19–21].
Both extrinsic and intrinsic pathways terminate at the execution phase in the 
final stage of apoptosis. Activated execution caspases further activates cytoplasmic 
Figure 1. 
Key components of the intrinsic and extrinsic pathways of apoptosis.
5
Insights into the Role of Defective Apoptosis in Cancer Pathogenesis and Therapy
DOI: http://dx.doi.org/10.5772/intechopen.97536
endonucleases, proteases that degrade nuclear and cytoplasmic proteins respec-
tively. The executioner caspases are caspase-3, caspase-6, and caspase-7 that cleave 
substrates like cytokeratins, PARP, and others that results in morphological and bio-
chemical changes in apoptotic cells. The most important of the executioner caspases 
is caspase-3 and is activated by any of the initiator caspases (caspase-8, caspase-9, 
or caspase-10). Caspase-3 induces cytoskeleton reorganization and disintegration 
of the cell into apoptotic bodies [22].
2.3 Perforin/granzyme pathway
The granzymes belong to a family of serine proteases contained in cytotoxic 
granules of innate and adaptive immune killer cells. The key function of these 
enzymes is eliminating viruses and tumor cells. They also regulate immune cells 
and inflammation by controlling the survival of lymphocytes. Granzymes are 
expressed by three gene clusters. Granzyme A and granzyme B are the most abun-
dant granzymes. Granzyme-mediated apoptosis is mainly used by lymphocytes to 
destroy virus infected cells. It is a kind of type IV hypersensitivity where sensitized 
CD8+ cells kill antigen-bearing cells. The FasL/FasR interaction is the predominant 
method of CTL-induced apoptosis. They also involve pathways that include secre-
tion of the transmembrane pore-forming molecule perforin with a subsequent 
release of cytoplasmic granules that have serine proteases as well as granzyme B, 
through the pore and into the target cell [23]. Granzyme B cleaves proteins at aspar-
tate residues and can activate pro-caspase-10. It can also cleave factors like ICAD 
(Inhibitor of Caspase Activated DNAse). Granzyme B can amplify the death signal 
by inducing cytochrome c release. It can also activate caspase-3 directly [24].
Therefore, in these types of pathways, signaling pathways that are upstream are 
bypassed and execution phase of apoptosis is directly influenced. It is suggested 
that both the mitochondrial pathway and direct activation of caspase-3 are critical 
for granzyme B induced killing activates both mitochondrial pathway and caspase-3 
activation [24, 25]. The immune cells that express highly variable and regulated 
patterns of granzymes include natural killer (NK) cells, cytotoxic CD4 and CD8 T 
cells, and regulatory T cells (Tregs). The granules contain perforin, to deliver the 
granzymes into the target cell. When cytotoxic T lymphocytes (CTLs) and NK cells 
form an immune synapse with a target cell for its elimination, cytotoxic granules 
join immune synapse where its membrane fuses with the killer cell membrane. 
This action results in the release of the granule contents into the synaptic cleft. The 
granzymes are then initiate distinct pathways of programmed cell death [8, 26, 27].
3. Bio markers of apoptosis
A biomarker is measured and evaluated to indicate normal or diseased biological 
processes. It has the potential to enhance translational progress and accelerate drug 
development. They allow monitoring of drug efficacy and also help in preclinical 
drug evaluation. It also allows early detection of toxicity during drug evaluation. 
The fragmentated DNA on agarose gel is a usual marker to detect apoptosis. The poly 
(ADP- ribose) polymerase (PARP) cleaved form, observed in cells undergoing apop-
tosis. Other markers are cytokeratin-18 cleavage by caspase 3. It may be detected by 
using the antibody M30. Cleavage of various caspases can be detected using flow 
cytometry during apoptosis [28, 29]. The widely used biomarkers of apoptosis, their 
methods of analysis and the specimen needed for analysis are discussed in Table 2. 
However, the use of these biomarkers as a tool to predict the occurrence of apoptosis 
in the pathogenesis of different diseases states warrants further investigation.
Regulation and Dysfunction of Apoptosis
6
4. Role of apoptosis in cancer
Cells can die in variety of ways which includes apoptosis, necrosis, mitotic catas-
trophe, senescence, and autophagy. Of these different modes of cell death, apoptosis 
is active, programmed and genetically controlled. While physiological apoptosis helps 
to eliminate genetically altered cells, defective apoptosis is intimately connected with 
cancer pathogenesis [30]. Apoptotic signaling regulation is important to preserve a 
proper balance between cell death and cell survival. It is also important in maintain-
ing genome integrity. The Apoptosis evasion is a prominent hallmark of cancer and 
cancer cells can use a number of diverse strategies to evade apoptosis. The disruption 
in the balance between pro- and anti-apoptotic proteins contributes to carcinogenesis 
[31]. It may be due to the reducing apoptosis in malignant cells [30]. For example, the 
imbalance between pro- and anti-apoptotic Bcl-2 proteins, its genetic and epigenetic 
alterations, can promote cancer cell survival. The elevated levels of anti-apoptotic 
family members is a distinct mechanism of apoptosis dysregulation in cancer. The 
anti-apoptotic proteins are widely over-expressed in cancer cells to overcome stress 
signals. Over-expression of anti-apoptotic Bcl-2 family proteins is often correlated 
with recurrence, poor prognosis, and resistance to cancer therapeutics [11].
miRNAs are a class of non-coding RNAs that regulate post-transcriptional gene 
expressions and silence target mRNAs. miRNAs dysregulation are associated with 
different human cancers and microRNAs (miRNAs) can function as oncogenes as 
well as tumor suppressors and their dysregulation are associated with many differ-
ent human cancers.. miRNAs target different mRNAs and act as anti-apoptotic or 
pro-apoptotic regulatots that involved in the apoptotic pathways [32]. For example, 
miR-15/16 targets the anti apoptotic factor (Bcl-2). In many cancers, the mostly up-
regulated miRNA is anti-apoptotic miRNA-21. It targets the programmed cell death 
4 gene (PCD 4 gene or PDCD4), tropomyosin 1 (TPM1), and the phosphatase and 
tensin homolog (PTEN), to modulate apoptosis. The application of anti-microRNAs 
imitate may act as a potent therapeutic strategy to inhibit key molecular signaling 
pathways that are present in cancer [32, 33].
Cancer cells often show dysregulated expression patterns of diverse long non-
coding RNAs (lncRNAs) in specific kinds of tumors. Therefore, their upexpression 
or down-regulation in cancer cells often sensitizes cells to apoptotic treatments. 
Biomarkers Analysis method Specimen for biomarker analysis





Detection by substrate active site activation
Cytokeratins ELISA
Flow cytometry
Biomarker in blood samples
Bcl-2, Bcl-xL ELISA
Flow cytometry





Early apoptotic event. It measures annexin 
that binds to the external ligand
Fas, Fas ligand ELISA
Flow cytometry
Expression on B and T cells, also expressed on 
normal and tumor tissues.
Granzyme B PET imaging Response in immunotherapy
8-hydroxy-2-deoxyguanosine, 
3-nitrotyrosine
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They also induce and modulate apoptosis. Therefore, targeting lncRNAs in can-
cer cells can be utilized for cancer treatment. Cellular-FLICE inhibitory protein 
(c-FLIP) is a critical negative regulator of the apoptotic pathway. The apoptosis 
regulation due to c-FLIP, mediated by the death receptors Fas, TNF-R1, DR4 and 
DR5. It exists in three isoforms that are derived from diverse mRNA splice variants. 
These splice variants are transcribed under the same promoter, namely c-FLIPL, 
c-FLIPS, and c-FLIPR. The three isoforms of c-FLIP acts at the DISC level and 
inhibit the procaspase 8 and 10 activation. C-FLIP high expression is found in many 
cancers and its downexpression can restore apoptosis mediated by TRAIL Aand 
CD95L. Thus, c-FLIP can act as a promising target for cancer therapy [34]. c-FLIP 
can also induce apoptosis at low and more physiologically relevant expression levels 
by recruiting at the DISC to increase caspase-8 activation.
NF-kB activation by CD40 ligand or TNF-α results in overexpression of c-FLIP 
and the prohibition of TNFR1, Fas- and TRAIL receptors induces apoptosis. 
Activation of several pathways, such as mitogen-activated protein kinase (MAPK), 
the phosphatidylinositol-3 kinase (PI3K)/Akt, can enhance the expression of c-FLIP 
and can hamper apoptosis induced by death receptors [35].
IAPs increase cell survival during cellular stresses such as ER stress and prevent 
both intrinsic and extrinsic apoptosis. Caspases dysregulation may inhibit apoptosis 
and carcinogenesis. Down-regulation of different caspases has been observed in 
many cancers. For example, caspase-9 and caspase-3 downregulation can leads 
to formation of different forms of cancers such as colorectal, ovarian, breast, and 
cervical cancers [36, 37].
5. Therapeutic targeting of defective apoptosis in cancer
Apoptosis plays a pivotal role in cancer pathogenesis. Therefore, understanding 
the molecular basis of defective apoptosis has garnered tremendous attention from 
medical researchers. Novel therapeutic agents and treatment modalities to modu-
late disease pathogenesis are under trials in both preclinical and clinical settings. 
An important strategy to modulate cancer pathogenesis involves the use of small 
molecule inhibitors (SMIs) that target specific components in apoptotic cascades.
5.1 Targeting anti-apoptotic Bcl-2 family members
Bcl-2 is over expressed in many types of tumors and imparts therapeutic 
intractability to such tumors. A highly selective inhibitor of Bcl-2 is Venetoclax. 
This drug has been approved for routine clinical practice and is currently in use for 
the treatment of ALL (acute lymphocytic leukemia), CLL (chronic lymphocytic 
leukemia), and multiple myeloma T-cell prolymphocytic leukemia. Venetoclax is 
a Bcl2-selective BH3-mimetic. BH3-mimetics represents a class of anticancer drug 
that mimic the functions of BH3-only proteins. These mimetics bind to prosurvival 
proteins like Bcl-2 and inhibit their ability to bind Bax or Bak [38]. Thus, when 
Bcl-2 overexpressing cancer cells are treated with venetoclax in vitro, the cancer 
cells undergo apoptosis. Venetoclax is often used alone or in combination with 
other drugs such as rituximab, ibrutinib, azacitidine/decitabine, and bortezomib/
dexamethasone against various hematological malignancies. Bcl-2 family members 
over expression are affiliated with aggressive cancer and chemo resistive [39]. 
These credentials make these proteins as highly encouraging therapeutic targets 
to develop pharmacological anticancer drugs. Bcl-2 family members inhibition by 
small interfering RNAs (siRNAs) may also induce apoptosis and can reduce tumor 
growth [40]. For example, Mcl-1 down regulation by siRNA induced significant 
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apoptosis in leukemia cells. Many different microRNAs have been associated that 
regulate Bcl-2 expression such as miR-195, miR-24-2, and miR-365-2 act as nega-
tive regulators of Bcl-2 family, which shows the therapeutic potential of these 
miRNAs [16, 41].
5.2 Mcl-1 inhibitors
The anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1) is an important 
regulator of apoptosis and a central driver of drug resistance in multitude of human 
malignancies. Overexpressed Mcl-1 imparts drug resistance of both solid tumors 
and hematological malignancies against various therapeutic agents. Several inhibi-
tors have been developed that show promising anticancer activities in preclinical 
and clinical settings. For example S63845 induces apoptosis in SCLC cell lines in 
vitro at an IC50 of 23 to 78 nM, while in xenograft models this molecule causes 
significant reduction in tumor volumes. S63845 can be used in combination with 
navitoclax (a dual inhibitor of Bcl-xL and Bcl-2) where S63845 reduced the cell 
viability of SCLC cells and showed synergistic effects in S63845-resistant xenograft 
models [42]. Furthermore, Mcl-1 is an attractive drug target in lung cancer due to 
its non-apoptotic involvement in DNA repair. Thus targeting Mcl-1 with a small 
molecule inhibitor (MI-233) blocks Mcl-1-mediated HR DNA repair and thereby 
sensitizes cancer cells to treatment induced replication stress. MI-233 shows strong 
synergism with hydroxyurea or olaparib in lung cancer models [43]. Similarly, 
targeted Mcl-1 inhibition by RNAi also increases caspase-mediated cell death in cell 
models such as ERα + breast cancer cells [44]. A specific Mcl-1 inhibitor VU661013 
induce tumor cell death and a causes synergistic reduction when used in combina-
tion with ABT-263 in tumor volume [45]. During the last several years, many Mcl-1 
inhibitors have been developed. However, due to large surface-exposed hydrophobic 
BH3 binding groove, specific targeting of Mcl-1 poses a big challenge. Thus indirect 
targeting of Mcl-1 is emerging as important mechanism of action of alternative 
drug classes such as CDK9 inhibitors or deubiquitination inhibitors [46]. The phar-
macological characteristics of the major Mcl-1 inhibitors are tabulated in Table 3.
5.3 X-linked inhibitor of apoptosis protein (XIAP) inhibitors
Although IAPs control plethora of signaling pathways, they were initially 
thought to be responsible for caspase inhibition by acting as negative regulators 
of apoptosis [36, 37]. Many small molecules have been designed to target the IAP 
proteins and one such category of an molecules is Smac mimetics (SMs). A recently 
developed XIAP inhibitor BMT-062789 displays remarkable anticancer activity 
against a panel of lymphoma cell lines. BMT-062789 is a heterodimeric mimetic of 
the second mitochondrial activator of caspases (SMAC) [47]. This molecule inhibits 
both the caspase 9 and caspase 3/7 binding domains of XIAP [48]. When used in 
combination with etoposide, BMT-062789 induces apoptosis in rituximab resistant 
cell line models Raji 4RH and RL 4RH. ASTX660 is another orally bioavailable, 
non-peptidomimetic antagonist of both XIAP and cellular IAP1 (cIAP1), with 
potential antineoplastic and pro-apoptotic activities. ASTX660 selectively binds to 
and inhibits the activity of XIAP and cIAP1 [49].
5.4 Caspase activators in cancer therapy
Caspases constitutes a group of cytosolic aspartate-specific cysteine proteases 
that participate in the initiation and execution of apoptosis Pharmacological 
activation of caspases using small molecule activators is an effective therapeutic 
9
Insights into the Role of Defective Apoptosis in Cancer Pathogenesis and Therapy
DOI: http://dx.doi.org/10.5772/intechopen.97536
strategy to kill cancer cells and can potentially help to reverse drug resistance. 
The most important cysteine protease in the caspase cascade is caspase 3 [50]. In a 
normal cell, capase-3 is typically in anactive form by an intramolecular electrostatic 
interaction favored by triplet of aspartic acid residues (also known as safety-catch). 
Although, there are indication that cell death can proceed in the absence of cas-
pases, activation caspase family members is critical for execution of cell death in 
apoptotic cells. Several drugs for activating caspases exist (Table 4). An important 
caspase-inducing agent is apoptin, which is a proline-rich protein capable of induc-
ing apoptosis in cancer cells in a selective manner. This protein is obtained from 
chicken anemia virus that causes tumor-specific apoptosis without interfering with 
normal cells. As such, apoptin is considered as a highly tumor-specific therapeutic 
agent [51, 52]. This drug is still in preclinical testing.
6. Conclusion
Due to its role in tissue homeostasis and cancer pathogenesis, apoptosis has 
received tremendous attention as a target for therapeutic intervention of cancer. 
Thus targeting apoptotic signaling networks is an important therapeutic strategy 
for cancer therapy. Many drugs have been developed that modulate different 
components of apoptotic signaling. However, many tumors ultimately develop 
Drug Affinity (Ki) Activity in tumors
S63845 Ki < 1.2 nM non-small cell lung cancer, breast cancer, 
melanoma
AMG 176 Ki = 0.06 nM breast cancer
AZD5991 Ki = 0.2 nM multiple myeloma, acute myeloid leukemia
VU661013 Ki = 97 ± 30 pM acute myeloid leukemia




Ki = 1.2–96.4 nM non-small cell lung cancer
Table 3. 
Pharmacological characteristics of some Mcl-1 inhibitors.
Caspase activator Mechanism of action
Cisplatin potent pro-apoptotic anticancer agent; activates 
caspase-3
α-(Trichloromethyl)-4-pyridineethanol (PETCM) activator of caspase-3
Apoptosis activator 2 promotes apoptosome formation and activates 





pro-apoptotic; activator of procaspase-3
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drug resistance against these drugs. Therefore there is a need to develop novel 
therapeutic agents and new treatment strategies that can reverse the drug-resistant 
phenotype of tumors and render these tumors sensitive towards therapeutic regi-
mens. A limited number of FDA-approved drugs exist that directly target apoptotic 
pathways. Many of these drugs target the Bcl-2 family member such as Bcl-2 itself 
and Mcl-1. Caspase 3 activators are also being tested in preclinical settings. Other 
therapeutic strategies involve the use of drugs that activate the extrinsic pathway 
of apoptosis or tumor suppressor pathways or modulate tumor microenvironment. 
However, it is interesting to conclude that apoptosis can be induced in cancer cells 
by activating both the intrinsic and extrinsic pathways of apoptosis. However there 
is a need to identify therapeutic targets that are unique to cancer cells so that their 
modulation may not affect the normal surrounding cells. Thus, while targeting 
apoptotic signaling networks, there is a need to ensure tumor-specific apoptosis 
without inducing apoptosis in normal cells. We are hopeful that, in future, a better 
understanding of apoptotic signaling may lead to the development of novel antican-
cer drugs that could target different components of apoptotic signaling selectively 
and specifically. However, the lack of precise relationship between level of proteins 
involved in apoptosis and the clinical outcome poses a big challenge in the develop-
ment of novel therapeutic agents and as such warrants in-depth understanding of 
apoptotic signaling networks.
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